Pacira BioSciences reports record 2022 revenue of $667M; Q4 GAAP net loss widens to $10.1M

Pacira BioSciences, Inc.

2022-FY EPS reported $0.34 revenue$666,823,000

Full-year 2022 revenue $666.8M (+23% YoY); GAAP net income $15.9M ($0.34 diluted EPS) vs $42.0M ($0.92) in 2021.
Q4 2022 revenue $172.0M (+8% YoY); GAAP net loss $10.1M ($0.22 loss per share) vs loss $5.1M in Q4 2021.
ZILRETTA net sales $105.5M full year; Q4 $28.0M (+121% YoY) driving growth. EXPAREL $536.9M (+6%) full year; Q4 $138.0M (-1%).
2023 guidance: EXPAREL net sales $570-580M, ZILRETTA $115-125M, non-GAAP gross margin 76-78%.
Submitted sNDA for EXPAREL sciatic/femoral nerve blocks; opened Houston Innovation & Training Center in Jan 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pacira BioSciences, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $172.0 million, net income $10.1 million, EPS $0.22 per basic and diluted share.

Period: the fourth quarter ended December 31, 2022
Revenue: $172.0 million
Net income: $10.1 million
EPS: $0.22 per basic and diluted share
Result: reported results

Exact text from the filing

Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share. • Fourth quarter GAAP net loss of $10.1 million or $0.22 per basic and diluted share.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pacira BioSciences, Inc. reported the full-year ended December 31, 2022 results: revenue $666.8 million, net income $15.9 million, EPS $0.35 per basic share and $0.34 per diluted share.

Period: the full-year ended December 31, 2022
Revenue: $666.8 million
Net income: $15.9 million
EPS: $0.35 per basic share and $0.34 per diluted share
Result: reported results

Exact text from the filing

Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share.

View on SEC.gov

Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.